News
Events
Further Study supports use of Nevisense within new Non-melanoma Skin Cancer application
February 5, 2021- A new clinical study from Germany including nearly 1,000 patients confirms the value of Nevisense when used to evaluate suspected Non-melanoma skin cancer (NMSC)
- The study publication is an important milestone in SciBase's strategy to broaden the areas of use and potential markets for Nevisense
The following people have been appointed as members of SciBase Holding’s nominating committee for the Annual General Meeting in 2021:
February 3, 2021Christer Jönsson (Fouriertransform), Iraj Arastoupour (Futur pension), Peter Elmvik, Tord Lendau (Chairman of the Board). The appointments have been made in accordance with the instructions regarding principles ...New Study published validating further Nevisense indication, Non-melanoma Skin Cancer
December 8, 2020New clinical study supports expansion of indications for Nevisense Study performed in Germany validates the use of Nevisense in non-melanoma skin cancer The study publication is an important milestone in the plan...- Load more news...